Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada
Catalyst Pharmaceuticals: Undervalued Cash Flow Generator With High Probability Of Outperformance
09:23am, Monday, 31'st May 2021
Catalyst Pharmaceuticals is a small cap biopharma company with a highly profitable ultra-orphan drug, Firdapse, for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS). Firdapse wa
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
08:03am, Wednesday, 19'th May 2021
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals' (CPRX) CEO Patrick McEnany on Q1 2021 Results - Earnings Call Transcript
01:51pm, Tuesday, 11'th May 2021
Catalyst Pharmaceuticals' (CPRX) CEO Patrick McEnany on Q1 2021 Results - Earnings Call Transcript
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
10:31am, Tuesday, 11'th May 2021
Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
08:17pm, Monday, 10'th May 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
05:29pm, Monday, 10'th May 2021
-Firdapse® Q1 2021 Net Revenues of $30.2 Million
This Under-the-Radar Pharma Company's Recent Success Is Just the Beginning
06:12am, Saturday, 08'th May 2021
Catalyst is facing its fair share of classic pharma challenges.
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to Decline
03:47pm, Monday, 03'rd May 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, de
Why Is Catalyst (CPRX) Up 8.9% Since Last Earnings Report?
12:11pm, Wednesday, 14'th Apr 2021
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
3 Magic Formula Stocks for the Value Investor
03:54pm, Sunday, 21'st Mar 2021
To increase one's chances of beating the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities
04:11pm, Wednesday, 17'th Mar 2021
Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2020 Results - Earnings Call Transcript
02:45pm, Tuesday, 16'th Mar 2021
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2020 Results - Earnings Call Transcript
